Immunizing with plasma to combat COVID-19
Universite de MontrealCanada institutions are pooling their scientific expertise to develop an extraordinary immunization program using passive plasma to fight COVID-19.
Canada institutions are pooling their scientific expertise to develop an extraordinary immunization program using passive plasma to fight COVID-19.
Bioengineers have created a blood-drawing robot that performed as well or better than technicians. The device could increase blood draw success from difficult- to-find veins and allow healthcare workers more time to treat patients.
Mount Sinai Health System is the first in the country to use an innovative allogeneic stem cell therapy in COVID-19 patients and will play a central role in developing and conducting a rigorous clinical trial for patients with severe acute respiratory distress syndrome, the breathing illness that afflicts people who have severe cases of COVID-19.
Novel 'learning while doing' clinical trial approach called REMAP helps doctors find the optimal trade-off between quickly adopting new therapies during a pandemic, such as the anti-malarial drug hydroxychloroquine, and waiting until they are tested in longer clinical trials. The trial announced today at UPMC, called UPMC-REMAP-COVID19 learns from similar trials enrolling around the world and uses artificial intelligence to quickly arrive at answers.
Washington University School of Medicine in St. Louis is launching a clinical trial for patients hospitalized with COVID-19 at Barnes-Jewish Hospital. The trial will investigate the effectiveness of different combinations of the antimalarial drugs chloroquine and hydroxychloroquine and the antibiotic azithromycin in treating ill patients infected with the novel coronavirus.
Researchers from Intermountain Healthcare and University of Utah Health in Salt Lake City have launched two vital clinical trials to test the effectiveness and safety of two drugs –hydroxychloroquine (HCQ) and azithromycin – to treat patients with COVID-19 (infection with the novel coronavirus).
Malaria is a leading killer of children worldwide, and new drugs are needed. New research reports encouraging early clinical results with a new compound.
A new form of magnetic brain stimulation rapidly relieved symptoms of severe depression in 90% of participants in a small study conducted by researchers at the Stanford University School of Medicine.
iNO has been used for the treatment of failing lungs, but it was also found to have antiviral properties against coronaviruses.The University of Alabama at Birmingham has been selected to begin enrolling patients in an international study assessing the use of inhaled nitric oxide (iNO) to improve outcomes for COVID-19 patients with severely damaged lungs.
A biomanufacturing company spun out of Cornell research is seeking to rapidly translate an antibody therapy against COVID-19 by using cell-free biotechnology based on glycoengineered bacteria. And it could scale up the production 10 times faster than conventional methods.
Ursolic acid, abundant in fruit peels and some herbs, both prevents and repairs neurons in animal models of multiple sclerosis.
A team of physician-scientists at Beth Israel Deaconess Medical Center are now enrolling patients in a clinical trial to evaluate a common anti-clotting drug for the treatment of COVID-19-positive patients with ARDS. The newly launched trial follows a special report the team published in the Journal of Trauma and Acute Care Surgery that suggested the use of a drug called tPA could reduce deaths among patients with ARDS as a complication of COVID-19.
Rush University Medical Center is participating in a new clinical trial to test the effectiveness of the drug remdesivir in the treatment of coronavirus disease 2019 (COVID-19).
New research from the Cancer Science Institute of Singapore at the National University of Singapore revealed a genetic variant in a gene called MET that is responsible for more aggressive growth of head and neck, and lung cancers in Asian populations.
UCLA Health is one of 75 sites around the globe participating in a clinical trial sponsored by the National Institutes of Health to test the effectiveness of a candidate anti-viral drug against COVID-19.
An international team led by University of British Columbia researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts.
Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, is offering a clinical trial as a potential treatment for patients diagnosed with the coronavirus (COVID-19). The trial, which is not limited to cancer patients is exploring hydroxychloroquine and azithromycin.
Montefiore Health System and Albert Einstein College of Medicine has joined a clinical trial to evaluate the experimental drug remdesivir to treat people who are hospitalized with severe COVID-19 infection.
Mardil Medical, Inc., today announced the successful completion of treatment for the third patient in the clinical trial of its improved VenTouch™ device.
Media are invited to attend and ask questions at this Virtual Press Conference with a Newswise Live Expert Panel to discuss the COVID-19 crisis.
Researchers and faculty from multiple disciplines across the University of Kentucky are coming together as part of the global effort to treat, understand and eradicate COVID-19. A new workgroup within UK’s College of Medicine is bringing together experts from across the campus to focus on advising COVID-19 patient care and clinical trials based on emerging research and potential treatment options.
An international collaboration of virologists at the University of Wisconsin–Madison and the vaccine companies FluGen and Bharat Biotech has begun the development and testing of a unique vaccine against COVID-19 called CoroFlu.
A study in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), published by Elsevier, reports that an entirely parent-based treatment, SPACE (Supportive Parenting for Anxious Childhood Emotions), is as efficacious as individual cognitive-behavioral therapy (CBT) for the treatment of childhood and adolescent anxiety disorders.
University Hospitals announced it will lead a clinical trial that involves the administration of an investigational drug, ARMS-I, to its caregivers working on the frontlines of the COVID-19 pandemic. The trial, named the ARMS-I COVID Study, is designed to assess whether the drug helps prevent airborne transmission of coronavirus and whether it reduces the symptoms of healthcare providers who have tested positive for the virus.
The University of Illinois at Chicago is participating in two clinical trials for COVID-19 treatments.
A subset of patients with metastatic prostate cancer and specific markers of immune activity responded well to treatment with immune checkpoint inhibitors, according to results of a Phase II trial.
Cedars-Sinai has joined an international effort to test an experimental antiviral drug as a potential treatment for COVID-19 (coronavirus). The institution expects to enroll its first clinical trial participant this week.
Liraglutide 3.0 mg, approved by the United States Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity to help adults with obesity manage their weight, appears to help adolescents too, according to an industry-sponsored randomized controlled trial. The study was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a supplemental issue of the Journal of the Endocrine Society.
Using a research assay called VirScan, scientists plan to study how antibodies from people who have had COVID-19 attack the virus that causes it.
Adults who need medical maintenance treatment of the growth hormone disorder acromegaly respond well to an investigational oral form of the drug octreotide, investigators of the Chiasma OPTIMAL study reported. Results of the phase 3 randomized controlled clinical trial were accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in the Journal of the Endocrine Society.
UC Davis Health physicians and medical staff who treated the first case of community transmission of COVID-19 in the U.S. provide a detailed case study of her condition and the medical steps and challenges they experienced before arriving at a diagnosis and treatment.
In a study involving thousands of participants, a new blood test detected more than 50 types of cancer as well as their location within the body with a high degree of accuracy, according to an international team of researchers led by Dana-Farber Cancer Institute and the Mayo Clinic.
Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19). The University of Tokyo announced these new findings on March 18, 2020.
A recent study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19.
A multi-site clinical trial, led by the University of Washington School of Medicine in collaboration with New York University Grossman School of Medicine, aims to definitively determine whether hydroxychloroquine can prevent transmission in people exposed to the virus.
UC Davis Health has two clinical trials underway for hospitalized patients with severe COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2.
Highly focused, intense doses of radiation called stereotactic ablative radiation (SABR) may slow progression of disease in a subset of men with hormone-sensitive prostate cancers that have spread to a few separate sites in the body, according to results of a phase II clinical trial of the therapy.
Removing a gene from the cells that produce insulin prevents mice from developing Type 1 diabetes by sparing the cells an attack from their own immune system, a new UW–Madison study shows.
SARS-CoV-2, the virus that causes COVID-19, continues to spread, leading to more than 20,000 deaths worldwide in less than four months. Efforts are progressing to develop a COVID-19 vaccine, but it's still likely 12 to 18 months away.
Physician-scientists at Beth Israel Deaconess Medical Center (BIDMC) are now enrolling patients in two clinical trials testing treatment options for COVID-19, the illness caused by the novel coronavirus. Two trials, led by infectious disease specialist Kathryn Stephenson, MD, MPH, will test the antiviral drug remdesivir for safety and efficacy against the respiratory infection that has sickened more than 300,000 and killed more than 15,000 around the world to date.
Researchers at four University of California Health medical centers have begun recruiting participants for a Phase II clinical trial to investigate the safety and efficacy of treating adult patients with COVID-19 with remdesivir, a drug that has shown promising activity against multiple viruses.
People who suffer cardiac arrest usually have low likelihood of survival, especially if it happens out of the hospital.
Expressive language sampling yielded five language-related outcome measures that may be useful for treatment studies in intellectual disabilities, especially fragile X syndrome. The measures were generally valid and reliable across the range of ages, IQs and autism symptom severity of participants. According to the study, led by UC Davis researchers and funded by NIH, the measures are also functional in supporting treatments that can improve language, providing far reaching benefits for individuals with intellectual disabilities.
Key factors must be taken into account in determining the need for and allocation of scarce ventilators during a severe pandemic, especially one causing respiratory illness.
Next generation genetic sequencing – or next generation sequencing (NGS) – is becoming more common in research, although it still isn’t widely available. At the UNC School of Medicine, it is part of a research collaboration to better understand viral lung infections, including COVID-19 – the novel coronavirus sweeping the world.
A new study from Washington University School of Medicine in St. Louis suggests that the age of certain immune cells used in immunotherapy plays a role in how effective it is. These cells — natural killer (NK) cells — appear to be more effective the earlier they are in development, opening the door to the possibility of an immunotherapy that would not utilize cells from the patient or a matched donor. Instead, they could be developed from existing supplies of what are called human pluripotent stem cells.
New study finds gene therapy improved cardiac, muscle and liver function in Danon disease mouse models.
Physicians describe the standardized procedure of surgical anesthesia for patients with COVID-19 infection requiring emergency surgery to minimize the risk of virus spread and reduce lung injury in a Letter to the Editor published in Surgical Infections, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Researchers from the University of Kentucky’s College of Medicine are leading a clinical study that could provide a promising new method for early detection of Parkinson’s disease.